Exciting update! The FDA has approved a new therapy to treat seizures for CDLK5 deficiency disorder (CDD), a rare epilepsy caused by mutations in the CDKL5 gene. The drug, Ztalmy® (ganaxolone), manufactured by Marinus Pharmaceuticals, is now approved to treat seizures associated with CDD in patients 2 years of age and older. This medication is the first FDA-approved treatment specifically for CDD. It is expected to be available to patients in July 2022.  

 
To learn more about this new drug treatment, please read here.